Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors.
Sailing ShiShengqing GuTong HanWubing ZhangLei HuangZiyi LiDeng PanJingxin FuJun GeMyles BrownPeng ZhangPeng JiangKai W WucherpfennigX Shirley LiuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Man2a1 loss renders cancer cells more susceptible to T-cell-mediated killing. Swainsonine synergizes with anti-PD-L1 in suppressing tumor growth. In light of the limited efficacy of anti-PD-L1 and failed phase II clinical trial on swainsonine, our study reveals a potential therapy combining the two to overcome tumor immune evasion.See related commentary by Bhat and Kabelitz, p. 5778.